Tilray shares technical analysis: Resistance test at $7.05

Traders Union
All News
Stocks
Tilray jumps 3.99% after expansion moves

Highlights

Tilray has expanded its global medical cannabis cultivation capacity to roughly 275 metric tonnes, supporting broader international supply capabilities.
The acquisition of HelloMD Corporation adds a digital healthcare platform, extending Tilray's access to medical cannabis patients.
Tilray stock trades in a range of $4.65 to $5.07 with strong short-term buying momentum but overbought technical signals.

Production expansion and HelloMD deal boost market access

Tilray has notably expanded its global medical cannabis cultivation capacity to approximately 275 metric tonnes, according to GlobeNewswire, directly enhancing its ability to supply both existing and emerging international markets. The recent 30 metric tonne increase at its Quebec facility further strengthens Tilray’s North American production base, which may improve operational efficiency and supply consistency for regional patients. In parallel, the completed acquisition of HelloMD Corporation on June 29, 2026, adds a digital healthcare and patient engagement platform that broadens the company's reach and access to medical cannabis patients.

Buyer momentum contrasts with overbought signals near resistance

TLRY/USD is trading above its MA-20 ($4.66) and MA-50 ($4.64) on the hourly chart, while remaining under the MA-200 ($7.05). The Ichimoku Kijun at $4.64 provides a layer of immediate support. MACD remains on a Buy signal and is accompanied by Bull/Bear Power and the Awesome Oscillator also generating Buy signals, reflecting buyer dominance. ADX is neutral, suggesting no strong underlying trend, while RSI sits at 66.11 and CCI is overbought, both hinting at early exhaustion. Stochastic RSI shows a neutral stance, signaling caution in momentum continuation.

High breakout risk as tight range and upside bias emerge

For the next several days, TLRY/USD is expected to trade within a projected range of $4.65–$5.07 based on typical volatility. The probability of an upward move is flagged as very high, while downside risk remains low. The baseline scenario anticipates consolidation within this corridor. A breakout above resistance could trigger further buying, whereas a drop below immediate support may put sellers back in control.

Anton Kharitonov, expert at Traders Union, notes that Tilray’s global capacity boost and completed acquisition improve its operational base and service channels, but the stock remains under key long-term resistance. He sees bullish technical signals, but also observes early signs of exhaustion and neutral trend strength. Baseline scenario favors range trading unless a breakout or breakdown emerges. "Until TLRY/USD breaks above the MA-200 at $7.05, I remain cautious and see short-term moves as consolidation rather than a clear bullish trend."

Previously it was reported that Tilray's expansion of medical cannabis production and acquisitions positioned the company to capitalize on increasing international demand, while technical indicators showed mixed momentum. The current technical setup continues to favor near-term consolidation, with any decisive move above or below the projected $4.65–$5.07 range likely determining the next directional bias for TLRY.

Source of Data: TLRY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.